Related Experiment Videos
Gender differences in pharmacokinetics and pharmacodynamics.
I Beierle1, B Meibohm, H Derendorf
1Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee, Memphis, USA.
International Journal of Clinical Pharmacology and Therapeutics
|December 10, 1999
Summary
Regulatory authorities now require women in clinical drug development to study gender differences in pharmacokinetics and pharmacodynamics. While some differences exist, they rarely impact clinical outcomes, questioning early-phase trial risks for women.
Area of Science:
- Pharmacology
- Clinical Drug Development
- Gender Studies
Background:
- Regulatory authorities mandated the inclusion of women in all clinical drug development phases to investigate sex-based pharmacokinetic and pharmacodynamic differences.
- Numerous studies have since evaluated the existence and impact of gender on clinical pharmacology, revealing varied findings.
Purpose of the Study:
- To review and synthesize the current understanding of gender differences in drug pharmacokinetics and pharmacodynamics.
- To assess the clinical relevance of identified gender-specific variations in drug response and safety.
Main Methods:
- Systematic review of published literature on gender differences in drug absorption, distribution, metabolism, and excretion (ADME).
- Analysis of pharmacodynamic studies examining sex-based variations in drug effects and therapeutic responses.
- Evaluation of clinical relevance and implications for drug development and patient care.
Main Results:
- Pharmacokinetic differences, particularly in oral bioavailability due to variations in metabolic enzyme activity, are noted but often lack major clinical relevance.
- Drug elimination processes show more frequent gender differences, linked to sex-specific metabolic enzyme expression (e.g., CYP3A4, CYP1A2), while renal elimination differences are minor.
- Pharmacodynamic variations in baseline characteristics and drug responses, influenced by sex hormones, are observed in areas like pain, glucose management, and arrhythmia susceptibility, though often masked by surrogate markers.
Conclusions:
- While including women in drug development is crucial, the clinical significance of identified pharmacokinetic and pharmacodynamic gender differences is often limited.
- Further research is needed to fully understand and address sex-specific drug responses, especially concerning potential risks in early-phase trials for women of childbearing potential.